HTA leaders press for equity and trust to become core decision rules
Health technology assessment has long been prized for rigorous methods, but this perspective argues that technical precision alone is no longer enough. Health technology assessment is increasingly being judged by whether it can justify decisions in a way patients, policymakers, and the public can recognize as fair. Persistent inequities, declining trust, and rapidly changing technologies now sit beside the traditional questions of value, budget impact, and comparative effectiveness.
The paper synthesizes Plenary Three of the HTAi 2025 Annual Meeting and pulls together multistakeholder views from patient advocacy, global health equity, health policy, industry, and HTA research. Its central message is blunt: transparency, equity, and trust cannot remain optional add-ons. They have to function as the ground rules for the process itself.
A purely technical HTA process can still produce socially uneven decisions.
Opaque deliberation weakens confidence even when the methods are rigorous
The article points to one of the field’s oldest vulnerabilities: deliberation that is rigorous inside the room but opaque outside it. HTA bodies may explain methods in detail, yet still leave patients and other stakeholders without a clear view of how trade-offs were actually made. In practice, that creates a gap between analytic excellence and public legitimacy.
This matters because HTA decisions often influence access to therapies, coverage policy, and reimbursement pathways. When the reasoning behind a recommendation is hard to follow, confidence erodes even if the statistical or economic analysis is sound. The consequence is not just confusion; it can also feed suspicion that decisions are driven by budget pressure or institutional habit rather than consistent principles.
The perspective also calls out limited feedback to patient contributors. Participation loses meaning when people are invited to speak but not told how their input shaped the outcome. In many systems, patient involvement is still treated as procedural participation rather than shared deliberation. The article argues for a stronger model in which contributors can see where their experience changed the discussion and where it did not.
Equity means different things in different systems, and HTA has to say so
One of the most difficult issues in HTA is that equity does not have a single universal definition. Different health systems face different burdens, financing structures, and social priorities. A fairness concern in one country may look quite different in another, especially when disparities are shaped by geography, income, ethnicity, sex, or access to specialist care.
The article treats this context dependence as a strength only if HTA bodies acknowledge it openly. If agencies pretend that equity is self-evident, they risk making assumptions that are invisible and therefore hard to challenge. Clearer definitions would allow stakeholders to debate not only whether equity is being considered, but which equity goals are being pursued and why.
That issue becomes even sharper when evidence bases do not reflect the populations most affected by real-world decisions. Trials and comparative datasets may underrepresent groups whose outcomes differ because of age, comorbidity, social disadvantage, or local health-system constraints. When the evidence base is narrow, the recommendation that follows can look universal while resting on a partial view of the patients who will live with it.
Diverse evidence and meaningful participation are linked, not separate tasks
The paper connects representation in evidence to representation in governance. If HTA draws mainly on data from populations that are already overrepresented in research, it will keep reproducing the same blind spots in coverage policy. Broader evidence collection is not only a scientific issue; it is a fairness issue because the people least visible in the data are often the people most affected by unequal access.
The same logic applies to multistakeholder engagement. The article draws on perspectives from patient groups, women’s global health advocates, policy experts, industry, and HTA specialists to show that legitimacy grows when decision-making is exposed to a wider range of experiences. These viewpoints do not erase methodological rigor. They make the reasoning more defensible by testing whether the process can stand up to scrutiny from more than one angle.
HTA can only claim social relevance if it listens to the people most likely to be excluded by standard evidence hierarchies.
Practical models already exist inside leading HTA bodies
The perspective does not stop at criticism. It points to emerging practices from leading HTA bodies that offer workable pathways forward. Those practices are framed as practical, not aspirational: clearer deliberative steps, better engagement with patients, and more explicit attention to equity in the assessment process.
Such moves may seem administrative, but they carry real clinical consequences. If HTA agencies make equity criteria explicit, they can influence which technologies are prioritized, how uncertainty is weighed, and how decision-makers respond when evidence is incomplete for specific subgroups. In a system built around scarce resources, the structure of the assessment process can shape who gets considered first and whose needs remain peripheral.
The article also suggests that HTA’s convening power is underused. Because HTA sits at the intersection of science, policy, and public accountability, it can do more than rank technologies. It can create a forum in which disagreements about value, fairness, and evidence quality are handled in the open rather than left to opaque administrative routines. That role is especially important now, as new technologies emerge faster than many health systems can assess them.
From technical gatekeeper to guardian of fairer systems
The conclusion is not that HTA should abandon rigor. It is that rigor without trust is incomplete. A process can be methodologically strong and still fail to earn confidence if affected communities cannot see how judgments were reached or whether their concerns were seriously weighed.
This perspective positions HTA as more than a gatekeeper. Its strongest claim is that HTA can help protect fairer health systems if transparency, equity, and trust are treated as foundational principles from the start. The piece is a call for institutions to make their values visible in the same way they already make their methods visible.
Its limits are equally clear. The article is a perspective built from a plenary discussion, not a comparative study of specific HTA reforms, so it does not quantify how much transparency or patient engagement changes outcomes across systems. What it does provide is a framework for judging future HTA decisions: if equity and trust are absent from the design, they are unlikely to appear in the result.